Alvotech said it will release first-quarter 2026 financial results on May 6, 2026, and host a webcast with live Q&A on May 7. The company said five biosimilars are already approved and marketed, with nine disclosed candidates in development.
The FDA issued a complete response letter rejecting Aldeyra Therapeutics' reproxalap for dry eye disease, marking the third rejection in three years due to inconsistent trial results and lack of substantial evidence of efficacy.
Alvotech announced successful clinical trial results for AVT80, a biosimilar to Takeda's Entyvio, meeting all primary endpoints. The company targets a $6.4 billion market opportunity with regulatory submissions planned.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07443683 |
Does Orientation On Eye Health To Female Health Volunteers Increase Footfall In A Vision Center |
RECRUITING | NA |
| NCT07434635 |
APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes |
RECRUITING | PHASE4 |
| NCT07327242 |
Effectiveness of a Large Language Model-Based Educational Tool on Visual Field Test Reliability in Glaucoma Patients |
ENROLLING_BY_INVITATION | NA |
| NCT07317661 |
Effectiveness of a Large Language Model-Based Educational Tool on Intraocular Lens Options |
ENROLLING_BY_INVITATION | NA |
| NCT06985264 |
Dry Eye in Upper Eyelid Surgery: Muscle Versus Fat Removal |
ENROLLING_BY_INVITATION | NA |
| NCT00953693 |
Patient Specific Induced Pluripotency Stem Cells (PSiPS) |
COMPLETED |
